秋水仙碱对脑梗死溶栓患者预后及炎症因子水平的影响

Effects of colchicine on prognosis and inflammatory factors levels in patients with cerebral infarction undergoing thrombolysis

目的探讨秋水仙碱对脑梗死溶栓患者预后及炎症因子水平的影响。方法抽取2021年8月至2023年3月在神经内科住院的144例接受阿替普酶溶栓治疗的脑梗死患者,随机将其分为对照组(70例)和试验组(74例)。对照组给予常规药物(阿司匹林和/或硫酸氢氯吡格雷+阿托伐他汀钙)治疗,试验组给予常规药物联合秋水仙碱治疗。比较两组的临床疗效、炎症因子水平及肝肾功能。结果试验组的临床疗效优于对照组,差异具有统计学意义(P<0.05)。试验组的超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平低于对照组,差异具有统计学意义(P<0.05)。治疗前、后,两组的谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐水平比较,差异无统计学意义(P>0.05);治疗后,两组的ALT、AST、肌酐水平高于治疗前,差异具有统计学意义(P<0.01)。结论秋水仙碱可改善脑梗死溶栓患者预后,降低hs-CRP、IL-6水平,且对肝肾功能无明显影响,具有较好的效果和安全性,值得临床推广。

Objective To explore the effects of colchicine on prognosis and inflammatory factors levels in patients with cerebral infarction undergoing thrombolysis.Methods A total of 144 patients with cerebral infarction who received alteplase thrombolysis therapy in the neurology department from August 2021 to March 2023 were selected and randomly divided into control group(70 cases)and experimental group(74 cases).The control group was treated with conventional drugs(aspirin and/or clopidogrel hydrogen sulfate+atorvastatin calcium),and the experimental group was treated with conventional drugs combined with colchicine.The clinical curative effect,inflammatory factors levels,liver and kidney function were compared between the two groups.Results The clinical curative effect of the experimental group was better than that of the control group,and the difference was statistically significant(P<0.05).The levels of hypersensitivity C-reactive protein(hs-CRP)and interleukin-6(IL-6)in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).Before and after treatment,there were no significant differences in the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST)and creatinine between the two groups(P>0.05);after treatment,the levels of ALT,AST and creatinine in the two groups were higher than those before treatment,and the differences were statistically significant(P<0.01).Conclusion Colchicine can improve the prognosis of patients with cerebral infarction undergoing thrombolysis,reduce the levels of hs-CRP and IL-6,and has no significant effect on liver and kidney function,with good effect and safety,which is worthy of clinical promotion.